ALTERITY THERAPEUTICS LTD
Business
ALTERITY THERAPEUTICS LTD develops first‑in‑class therapies targeting neurodegenerative diseases. It focuses on small‑molecule drug candidates, principally ATH434, designed to redistribute labile iron, inhibit α‑synuclein aggregation and preserve neurons, and earlier zinc ionophores and PBT2‑derived assets. Its business comprises research and development, discovery chemistry and translational biology programs, clinical development including Phase 2 trials in Multiple System Atrophy and preclinical Parkinson’s programs. Alterity conducts activities through collaborations with research institutions and via clinical trials and regulatory interactions in Australia, the United States, Europe and other markets.
Summary from filing dated 2025-08-29
Financials
Latest annual snapshot (FY2025, period end 2025-06-30). Full statement history unavailable for this entity.
| Revenue | — |
| Net income | $-12.15M |
| Total assets | $46.03M |
| Total liabilities | $3.62M |
| Stockholders' equity | — |
| Operating cash flow | — |